INOmax

Parents FLEXtraNet

Contact Us

INOMAX^® Customer Care
Open 24 hours, 7 days a week
Tel: 1-877-KNOW-INO (1-877-566-9466)
Email: info@ikaria.com
We're here to help

Ikaria does not share personal information provided by users of the INOMAX website with any third party.

If you would like to contact us through the form below, please do not use it to report adverse events. Adverse event reporting should be directed to our Customer Care Department (see sidebar information).

Request Information

Let us know how we can help and we’ll quickly supply you with whatever information you are looking for. * Indicates required field.

Select one*

Delivery System Information

General Information

INOMAX Information

Medical Information

Reimbursement

International Contacts

Prefix: First Name*:

Last Name*

Title*

Facility*

Address 1*

Address 2

City*

State/Province*

Zip code*

Country*

Are you a resident of the US?*YesNo

Phone*

Fax

Email*

Check if you are a healthcare professional involved with the prescribing and delivery of INOMAX (nitric oxide) for inhalation.

Specific medical information requested and/or questions*

Yes! I want to receive important news and information regarding INOMAX.

© 2012 Ikaria, Inc.
Ikaria Corporate Headquarters
Perryville III Corporate Park | 53 Frontage Road, Third Floor | PO Box 9001 | Hampton, NJ
Tel: 908-238-6600 | Fax: 908-238-6633

INOMAX^®, INOvent^®, INOtherapy^®, INOcal^®, and INOmeter^®are registered trademarks of INO Therapeutics LLC.

DS_IR^® is a registered trademark of Ikaria, Inc.

The product information provided in this site is intended only for residents of the United States.
The product discussed herein may have different product labeling in different countries.

INOMAX^® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX Important Safety Information

INOMAX must not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
Nitrogen dioxide (NO₂) rapidly forms in gas mixtures containing nitric oxide and oxygen. NO₂ formed in this way can cause airway inflammation and damage
INOMAX must be administered through a system that does not cause excessive generation of NO₂ and that monitors for NO, NO₂, and FiO₂
Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO₂ and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema

Please see Full Prescribing Information.

Refer a Colleague to INOMAX^®

Disclaimer

*Please note: When you access these resources, you are leaving the INOMAX website. Therefore, Ikaria Inc. does not endorse the accuracy of the information you may find. We encourage you to talk to your doctor about the accuracy of any information you discover through these Internet resources.

Agree and continue →

Contact Us

Refer a Colleague to INOMAX®

Get INOMAX® Email Updates

Disclaimer

Refer a Colleague to INOMAX^®

Get INOMAX^® Email Updates